Investigational drug · Phase 3
Giredestrant
Also called: RO7197597, GDC-9545, RG6171
Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
16
15 still active
All registered trials
30
Any phase or sponsor naming "Giredestrant"
First trial start
2018
Mar 30, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Giredestrant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Early Breast Cancer
- Breast Cancer
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Metastatic Breast Cancer
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
- Ovarian Cancer
- Estrogen Receptor-Positive Breast Cancer
- HER2-Negative Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Giredestrant" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerPivotal-lookingNot yet recruiting
PfizerPfizer (PFE)
NCT07890597 · 3,800 participants (planned) · Start Dec 1, 2026 · Primary completion Apr 13, 2032
Drug: Atirmociclib; giredestrant · For: Early Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07827573 · 1,500 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: Giredestrant · For: Early Breast Cancer; Estrogen Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
Sites: Salem, Oregon; Richmond, Virginia; Montreal, Canada · 4 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06065748 · 1,050 participants (planned) · Start Dec 11, 2023 · Primary completion Apr 20, 2028
Drug: Giredestrant; Fulvestrant and 4 more · For: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sites: Daphne, Alabama; Greenbrae, California; Harbor City, California · 311 sites in all
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04546009 · 992 participants · Start Oct 9, 2020 · Primary completion Jan 30, 2026
Drug: Giredestrant; Giredestrant-matched Placebo and 4 more · For: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Sites: Fountain Valley, California; Long Beach, California; San Leandro, California · 256 sites in all
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruiting
MedSIRAcademic, hospital or other
NCT05708235 · 976 participants (planned) · Start Apr 1, 2024 · Primary completion Jun 30, 2028
Drug: Giredestrant; Abemaciclib and 2 more · For: Breast Cancer
Sites: A Coruña, Spain; Alicante, Spain; Barcelona, Spain · 41 sites in all
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05296798 · 922 participants (planned) · Start Jul 18, 2022 · Primary completion Jun 15, 2028
Drug: Phesgo; Giredestrant and 4 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Tucson, Arizona; Los Angeles, California; Jacksonville, Florida · 198 sites in all
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruiting
PfizerPfizer (PFE)
NCT04557449 · 430 participants (planned) · Start Sep 23, 2020 · Primary completion Oct 7, 2029
Drug: PF-07220060 · For: Liposarcoma; Prostate Cancer; Advanced Breast Cancer and 2 more
Sites: Los Angeles, California; New Haven, Connecticut; Trumbull, Connecticut · 39 sites in all
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Pivotal-lookingActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05306340 · 373 participants · Start Aug 3, 2022 · Primary completion Jul 16, 2025
Drug: Giredestrant; Exemestane and 5 more · For: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Little Rock, Arkansas · 136 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Giredestrant plus Everolimus in Advanced Breast Cancer.
Mayer EL, Tolaney SM, Martín M, et al. · N Engl J Med 2026
- Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence.
Guan B, Zhang S, Zhou R, et al. · Front Oncol 2026
- Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.
Alasheev AY, Hamama R, Petersen EV, et al. · Front Oncol 2026
- Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers.
Zhou W, Ahmed M, Guan J, et al. · Cell Chem Biol 2026
- Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer.
Liang J, Ong C, Heslop K, et al. · Nat Commun 2026
- ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.
Collier AE, Hilz S, Chibly AM, et al. · Nat Commun 2026
Also in development for Early Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Fixed of PertuzumabPhase 31 trial
Roche (Genentech) · Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.